印度的癌症试验增长尽管取得了经济成就,但仍停滞不前,这与其他发展中国家不同。 India’s cancer trial growth stalled despite economic gains, unlike some other developing nations.

CANCER的一项新研究发现,尽管印度自2001年以来取得了经济增长,但其癌症临床试验活动却增长不均,从2001-2005年的54个试验增加到2016-2020年的126个试验,全国共有506个试验。 A new study in CANCER finds that despite India’s economic growth since 2001, its cancer clinical trial activity has grown unevenly, rising from 54 to 126 trials between 2001–2005 and 2016–2020, with a total of 506 trials nationwide. 虽然二十年来中低收入国家的癌症试验在全球从1,053例增加到7,661例,但进展差异很大。 While low- and middle-income countries saw a global increase in cancer trials from 1,053 to 7,661 over two decades, progress varied widely. 中国和韩国等国家将经济扩张与更有力、更复杂的研究联系起来,但印度、泰国和越南没有取得类似的成果。 Countries like China and South Korea linked economic expansion to stronger, more complex research, but India, Thailand, and Vietnam did not achieve similar gains. 相反,巴西、阿根廷和墨西哥尽管经济停滞,却扩大了审判范围,埃及的增长与发展相一致,而南非则没有。 In contrast, Brazil, Argentina, and Mexico expanded trials despite economic stagnation, and Egypt saw growth aligned with development, while South Africa did not. 研究报告的结论认为,仅靠经济增长并不能确保强有力的临床研究,并呼吁进行有针对性的投资,以改善发展中国家接受癌症试验的机会和基础设施。 The study concludes that economic growth alone does not ensure robust clinical research and calls for targeted investments to improve cancer trial access and infrastructure in developing nations.